Previous close | 126.93 |
Open | N/A |
Bid | 139.20 |
Ask | 144.80 |
Strike | 270.00 |
Expiry date | 2025-01-17 |
Day's range | 126.93 - 126.93 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a single dose for individuals 5 years of age and older, regardless of COVID-19 vaccination history. In children 6 months through 4 years of age the vaccine is administered as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose in thos
The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.